ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1218

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients

Rehan Azeem1, Justin Park 1, Horacio Plotkin 1, Alan Kivitz 2, Lloyd Johnston 1, Takashi K. Kishimoto 1, Stephen Smolinski 1 and Wesley DeHaan 1, 1Selecta Biosciences, Watertown, MA, 2Altoona Center for Clinical Research, Duncansville, PA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: clinical trials, drug therapy, gout, immune response and tolerance

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Long term gout treatment focuses on reducing sUA levels, thus allowing MSU crystals to dissolve. Rapid dissolution of MSU crystals during initial phase of urate lowering therapy (ULT) is associated with an increased incidence (75%) and frequency (2.1 flares/patient/month)* of acute gout flares contributing to poor treatment compliance. During ULT initiation, colchicine, NSAIDs or corticosteroids are used for gout flare prophylaxis. Pegylated uricases are therapies for the treatment of chronic gout. However, their efficacy and safety are limited by induction of anti-drug antibodies (ADA). SEL-212 is a novel combination product consisting of pegadricase co-administered with proprietary ImmTOR tolerogenic nanoparticles. We report here data on gout flares from a Phase 2 study in symptomatic gout patients.

Methods: Patients with symptomatic gout (≥1 tophus, gout flare within 6 months or gouty arthropathy) and elevated serum uric acid (sUA) ≥6 mg/dL were randomized to receive  doses of pegadricase (0.2 mg/kg or 0.4 mg/kg) alone or in combination with ImmTOR (0.05 to 0.15 mg/kg).  Treatments were administered intravenously monthly for 3 cycles of SEL-212, followed by 2 additional cycles with pegadricase alone or SEL-212. Safety, tolerability, sUA, and ADAs were monitored. Here we report on the patients that received 5 combination doses of ImmTOR and pegadricase.

94% (49/52) of all randomized patients received premedication for gout flare prevention as per standard of care in the form of colchicine (1.2 mg as loading dose, 0.6 mg QD for the remainder of their participation), ibuprofen, or equivalent dose of NSAID.

Results: Demographics of 46 patients treated with 28-day cycles x5 combination doses of ImmTOR and pegadricase as compared to 6 patients treated with pegadricase alone were 23-70 years old vs. 41-64 years old (mean 53.6 vs. 51.8 years), male 97.8% vs. 100%, and white 73.9%. vs. 33.3%. The mean BMI at baseline was 34.5 vs. 38.9 kg/m2. 71.7% vs. 100% of patients were obese with mean duration of established or symptomatic gout was 12.5 vs. 12.8 years. 43 patients were evaluable for gout flare analysis.

In the first month 50% of patients who received pegadricase alone had flares compared to 35% receiving SEL-212. There were no patients with initial flares after second month of treatment.

Data analyzed as combined months in patients receiving SEL-212, showed flare incidence of 37.0% (months 1-3) and 13.6% (months 4-5), flare frequency was 0.83 flares/patient (months 1-3) and 0.27 flares/patient (months 4-5). Mean duration of the gout flares was 6.1 days, with majority of the gout flares (97.7%) being categorized as mild/moderate, with 2.3% (n=1) noted as severe in intensity. Adjustments to gout flare prevention medication were not required for 69.6% of the patients. No gout flares resulted in patient discontinuation or were reported as a study drug related serious adverse event.

Conclusion: Monthly dosing of ImmTOR combined with pegadricase has been well-tolerated and has a lower incidence of flares at the initiation of therapy relative to pegylated uricases alone and the reported ULT flare incidence, and the effect persists over the duration of therapy.

*JAMA. 2011;306(7):711-720

% of Patients with Flare by Treatment Month


Disclosure: R. Azeem, Selecta Biosciences, 1, 3; J. Park, Selecta Biosciences, 1, 3; H. Plotkin, Selecta Biosciences, 1, 3; A. Kivitz, AbbVie, 5, Amgen, 1, 4, 5, Boehringer Ingeleheim, 5, Boehringer Ingelheim, 5, Celgene, 8, Flexion, 5, 8, Flexion Therapeutics, 8, Genzyme, 5, 8, Gilead, 1, 4, 5, Gilead Sciences, Inc., 4, Horizon, 8, Janssen, 5, Janssen Research & Development, LLC, 2, Merck, 8, Novartis, 1, 4, 8, Pfizer, 1, 4, 5, 8, Regeneron, 1, 5, 8, Sanofi, 1, 4, 5, 8, Sun Pharma, 5, SUN Pharma Advanced Research, 5, UCB, 5; L. Johnston, Selecta Biosciences, 1, 3; T. Kishimoto, Selecta Biosciences, 1, 3; S. Smolinski, Selecta Biosciences, 1, 3; W. DeHaan, Selecta Biosciences, 1, 3.

To cite this abstract in AMA style:

Azeem R, Park J, Plotkin H, Kivitz A, Johnston L, Kishimoto T, Smolinski S, DeHaan W. Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/monthly-dosing-of-immtor-tolerogenic-nanoparticles-combined-with-pegylated-uricase-pegadricase-enables-sustained-reduction-of-acute-gout-flares-in-symptomatic-gout-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/monthly-dosing-of-immtor-tolerogenic-nanoparticles-combined-with-pegylated-uricase-pegadricase-enables-sustained-reduction-of-acute-gout-flares-in-symptomatic-gout-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology